Trial Profile
A retrospective study evaluating sustained virologic response rates (SVR-12) for chronic hepatitis C genotype 6 patients treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018